Fundraising Fox
Molecular Stethoscope
San Diego, US · Founded 2015 · Delaware corporation · 2 known investors
Find your way into Molecular Stethoscope
Sign up to see every warm intro you have to Molecular Stethoscope
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Molecular Stethoscope team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Molecular Stethoscope (Superfluid) develops a cell-free messenger RNA (cf-mRNA) "liquid biopsy" blood-based diagnostic platform for detecting neurodegenerative diseases, currently focused on early-stage Alzheimer's disease. The minimally invasive approach aims to replace spinal taps and brain scans, enabling repeated monitoring of a patient's disease state to guide therapy.
Founders & leadership
GM
Guillermo M. Elias, Ph.D.Executive
SQ
Stephen Quake, D. Phil.Named on SEC filing
Board
AM
Arda Minocherhomjee, Ph.D.Board director
TS
Tina S. Nova, Ph.D.Board director
Investors · 2
Funding
SEC filings, press & company announcements$4.5M disclosed across 1 of 2 rounds · 2017–2019
- Undisclosed amountSeedJan 2017Source ↗
▶$4.5MraisedOct 2019 · 15 investors · BiotechnologyRule 506(b)
▶$4.5MraisedOct 2019 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen Quake, D. Phil.Director
- Guillermo M. Elias, Ph.D.Executive Officer
- Arda Minocherhomjee, Ph.D.Director
- Tina S. Nova, Ph.D.Director
- Offering amount
- $5.6M
- Amount sold
- $4.5M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Molecular Stethoscope do?
- Molecular Stethoscope (Superfluid) develops a cell-free messenger RNA (cf-mRNA) "liquid biopsy" blood-based diagnostic platform for detecting neurodegenerative diseases, currently focused on early-stage Alzheimer's disease. The minimally invasive approach aims to replace spinal taps and brain scans, enabling repeated monitoring of a patient's disease state to guide therapy.
- Who are Molecular Stethoscope's investors?
- Molecular Stethoscope's investors include AAF Management Ltd., DCVC (Data Collective).
- How much funding has Molecular Stethoscope raised?
- Molecular Stethoscope has disclosed $4.5M raised across 1 of its 2 known rounds.
- Where is Molecular Stethoscope headquartered?
- Molecular Stethoscope is headquartered in San Diego, US.